Prophylaxis and treatment of angioedema
AssigneePharvaris GmbH
InventorsAnne Lesage, Peng Lu
Life of this patent
Estimating the term…
Abstract
The invention relates to a bradykinin (BK) B2-receptor antagonist having structural formula (I) for use in prophylactic treatment of angioedema (AE) or in a method of treating AE, wherein said compound is at least once orally administered in a therapeutically effective dose to prevent, alleviate or treat AE symptoms. This invention also provides a method of prophylactic treatment of a human patient suffering from AE or a method for on-demand treatment of a human patient who has experienced an acute AE attack, comprising orally administering to the human patient a therapeutically effective dose of the compound of formula (I) at least once to thereby alleviate or treat AE symptoms of the patient.
Claims17
A method of treating or preventing a bradykinin-mediated disorder in a human comprising orally administering to the human with a bradykinin-mediated disorder a compound having the following structural formula (I):
- or a pharmaceutically acceptable salt, or solvate thereof:
- at a dose of 10 to 50 mg of the compound having structural formula (I), wherein the bradykinin-mediated disorder is angioedema (AE), and wherein the compound is administered on-demand, daily, or both.
A kit containing:
- (i) a pharmaceutical unit dosage composition comprising a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, or solvate thereof;
- and (ii) a pharmaceutical unit dosage composition comprising a therapeutically effective amount of a CYP3A4 CYP34A inhibitor, or a pharmaceutically acceptable salt, or solvate thereof.
Dependencies are inferred from the claim text.